Skip to content

Study to find out if restricting raw fruits in patients with blood cancer can reduce infections.

Phase 3 randomised controlled trial comparing the effectiveness of restricting raw fruits from the diet of patients undergoing induction chemotherapy for acute leukemia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011418
Enrollment
200
Registered
2018-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL] Health Condition 2: C920- Acute myeloblastic leukemia Health Condition 3: null- Patients with acute lymphoblastic leukemia or acute myeloid leukemia

Interventions

Intervention1: Restricted diet group: Patient will consume a balanced diet containing only completely cooked freshly prepared food. All raw food (fruit, vegetables, dairy products, eggs, meat and othe

Sponsors

Cancer Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients 1 year to 60 years of age 2. Diagnosed with either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) 3. Patient should be able to consume normal diet orally 4. No evidence of infection at the time of randomization (clinically, radiologically or microbiologically) 5. In case of age less than 18 years, parent/guardian (legally authorized representative) agrees to the patientâ??s participation as indicated by parent/legal guardian signature on the informed consent form. 6. Signed informed consent in patients more than 18 years of age 7. Patient is scheduled to receive induction chemotherapy for ALL or AML as per the protocol with curative intent. 8. Patient >10 years of age has a Karnofsky score >=60; patient =60.

Exclusion criteria

Exclusion criteria: 1. Patient is pregnant or breast feeding. (Females of child bearing potential are required to have a negative urine pregnancy test prior to entering the study). 2. Patients with relapsed leukemia. 3. SGOT (AST) > 5.0 x upper limit of normal (ULN) and SGPT (ALT) >5.0 x ULN and Bilirubin >1.5 x ULN. 4. Serum creatinine > ULN. 5. Patient has an active infection (e.g., pneumonia, diarrhoea, urinary tract infection, cellulitis, meningitis, otitis media and sinusistis). 6. Congestive heart failure, bradyarrythmia, ischemic heart disease, uncontrolled diabetes mellitus or hypertension. 7. Gastrointestinal obstruction, malabsorption syndrome or persistent vomiting. 8. Patient is mentally incapacitated or has a significant emotional or psychiatric disorder that, in the opinion of the investigator, precludes study entry. 9. Palliative intent of treatment or planned reduction in intensity of treatment due to co-morbidities or poor performance status.

Design outcomes

Primary

MeasureTime frame
To compare the incidence of infectious episodes and fever between the restricted diet and regular diet group.Timepoint: Patients will be censored in the trial at the following instances 1. Completion of induction chemotherapy and discharge from hospital or day 40 of induction chemotherapy, whichever is earlier. 2. Death occurring within 40 days of starting induction chemotherapy. 3. Patient withdraws from the trial.

Secondary

MeasureTime frame
To assess the prevalence of multi drug resistance (MDR) bacteria in stool culture at admission and on day 15 of induction and correlate with blood culture positivity. To assess the impact of restricted diet vs regular diet on stool microbial flora in patients undergoing induction chemotherapy for acute leukemia. Timepoint: Patients will be censored in the trial at the following instances 1. Completion of induction chemotherapy and discharge from hospital or day 40 of induction chemotherapy, whichever is earlier. 2. Death occurring within 40 days of starting induction chemotherapy. 3. Patient withdraws from the trial.

Countries

India

Contacts

Public ContactVenkatraman Radhakrishnan

Cancer Institute (WIA), Chennai, India

venkymd@gmail.com9498082771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026